Odyssey Health, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Odyssey Health reports a net income of $765,890 for the quarter ended April 30, 2026, while maintaining a going concern warning due to significant accumulated deficits.
OQB
Odyssey Health, Inc. reported a reduced net loss for the first quarter of fiscal 2026 but continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and negative working capital.
OQB
Odyssey Health, Inc. reported a significant net loss for the nine months ended April 30, 2025, and disclosed substantial doubt about its ability to continue as a going concern due to recurring operating losses and negative cash flows.
OQB
Odyssey Health's Q2 2025 report reveals ongoing losses and a focus on securing additional funding to continue operations and product development.
OQB
Odyssey Health reported a net loss of $1.019 million for the quarter ended October 31, 2024, and faces substantial doubt about its ability to continue as a going concern.
OQB
Odyssey Health's Q3 2024 report details a significant asset sale to Oragenics, impacting financials and future strategy, alongside ongoing financial challenges.
OQB
Odyssey Health, Inc. reports a net income of $12.7 million for the six months ended January 31, 2024, driven by a significant gain from the sale of assets to Oragenics, Inc.